Novel oral anticoagulants in gastroenterology practice

Gastrointestinal Endoscopy

Volumn 78, Issue 2, 2013, Pages 227-239

  Desai, Jay ^a   Granger, Christopher B ^b   Weitz, Jeffrey I ^c   Aisenberg, James ^d  

^a NEW YORK UNIVERSITY   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c MCMASTER UNIVERSITY   (Canada)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

activated partial thromboplastin time; AF; American Society for Gastrointestinal Endoscopy; apixaban for reduction in stroke and thromboembolic events in atrial fibrillation; aPTT; ARISTOTLE; ASGE; atrial fibrillation; INR; international normalized ratio; NOAC; nonsteroidal anti inflammatory drug; novel oral anticoagulant; NSAID; PCC; PPI; prothrombin complex concentrate; prothrombin time; proton pump inhibitor; PT; randomized evaluation of long term anticoagulant therapy; RE LY; relative risk; rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation; ROCKET AF; RR

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN ETEXILATE; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; CEREBROVASCULAR ACCIDENT; DRUG ABSORPTION; DRUG APPROVAL; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG RELEASE; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

ACTIVATED PARTIAL THROMBOPLASTIN TIME; AF; AMERICAN SOCIETY FOR GASTROINTESTINAL ENDOSCOPY; APIXABAN FOR REDUCTION IN STROKE AND THROMBOEMBOLIC EVENTS IN ATRIAL FIBRILLATION; APTT; ARISTOTLE; ASGE; ATRIAL FIBRILLATION; INR; INTERNATIONAL NORMALIZED RATIO; NOAC; NONSTEROIDAL ANTI-INFLAMMATORY DRUG; NOVEL ORAL ANTICOAGULANT; NSAID; PCC; PPI; PROTHROMBIN COMPLEX CONCENTRATE; PROTHROMBIN TIME; PROTON PUMP INHIBITOR; PT; RANDOMIZED EVALUATION OF LONG TERM ANTICOAGULANT THERAPY; RE-LY; RELATIVE RISK; RIVAROXABAN ONCE DAILY ORAL DIRECT FACTOR XA INHIBITION COMPARED WITH VITAMIN K ANTAGONISM FOR PREVENTION OF STROKE AND EMBOLISM TRIAL IN ATRIAL FIBRILLATION; ROCKET-AF; RR;

ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; GASTROINTESTINAL HEMORRHAGE; HUMANS; MORPHOLINES; PYRAZOLES; PYRIDINES; PYRIDONES; STROKE; THIOPHENES;

EID: 84880276047     PISSN: 00165107     EISSN: 10976779     Source Type: Journal    
DOI: 10.1016/j.gie.2013.04.179     Document Type: Review

References (77)

1. W. Rosamond, K. Flegal, and K. Furie Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation 117 2008 e25-146
2. P.A. Wolf, R.B. D'Agostino, and A.J. Belanger Probability of stroke: a risk profile from the Framingham Study Stroke 22 1991 312 318
3. R.G. Hart, O. Benavente, and R. McBride Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis Ann Int Med 131 1999 492 501
4. S. Blech, T. Ebner, and E. Ludwig-Schwellinger The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans Drug Metab Disposit 36 2008 386 399
5. T.S. Potpara, G.Y.H. Lip, and S. Apostolakis New anticoagulant treatments to protect against stroke in atrial fibrillation Heart (British Cardiac Society) 98 2012 1341 1347
6. M. Ganetsky, K.M. Babu, and S.D. Salhanick Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant J Med Toxicol 7 2011 281 287
7. R. Kreutz Pharmacodynamic and pharmacokinetic basics of rivaroxaban Fund Clin Pharmacol 26 2012 27 32
8. D. Kubitza, M. Becka, and A. Roth Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects Current medical research and opinion 24 2008 2757 2765
9. C. Weinz, T. Schwarz, and D. Kubitza Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans Drug Metabol Disposit 37 2009 1056 1064
10. K.T. Moore, A.N. Plotnikov, and A. Thyssen Effect of multiple doses of omeprazole on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban J Cardiovasc Pharmacol 58 2011 581 588
11. N. Raghavan, C.E. Frost, and Z. Yu Apixaban metabolism and pharmacokinetics after oral administration to humans Amer Soc Pharm Exp Thera 37 2009 74 81
12. C. Frost, J. Wang, and A. Schuster Apixaban, an oral, direct factor Xa inhibitor: single-dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects Br J Clin Pharmacol 75 2013 476 487
13. Eliquis 2.5 mg film-coated tablets - Summary of Product Characteristics (SPC) - (eMC) [Internet]. 2012. Accessed Dec 15, 2012. Available from: http://www.medicines.org.uk/EMC/medicine/24988/SPC/Eliquis+2. 5+mg+film-coated+tablets.
14. J.W. Eikelboom, L. Wallentin, and S.J. Connolly Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial Circulation 123 2011 2363 2372
15. FDA Briefing Document for the Cardiovascular and Renal Drugs Advisory Committee (CRDAC) Rivaroxaban 2012 Janssen Pharmaceuticals, Inc.
16. S.H. Hohnloser, Z. Hijazi, and L. Thomas Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial Eur Heart J 33 2012 2821 2830
17. L.L. Strate Lower GI bleeding: epidemiology and diagnosis Gastroenterology Clin N Am 34 2005 643 664
18. C.I. Coleman, D.M. Sobieraj, and S. Winkler Effect of pharmacological therapies for stroke prevention on major gastrointestinal bleeding in patients with atrial fibrillation Int J Clin Pract 66 2012 53 63
19. R. Marmo, M. Koch, and L. Cipolletta Predictive factors of mortality from nonvariceal upper gastrointestinal hemorrhage: a multicenter study Am J Gastroenterol 103 2008 1639 1647
20. F. Radaelli, S. Paggi, and V. Terruzzi Management of warfarin-associated coagulopathy in patients with acute gastrointestinal bleeding: a cross-sectional physician survey of current practice Dig Liver Dis 43 2011 444 447
21. C.P. Choudari, C. Rajgopal, and K.R. Palmer Acute gastrointestinal haemorrhage in anticoagulated patients: diagnoses and response to endoscopic treatment Gut 35 1994 464 466
22. C.M. Wilcox, and C.D. Truss Gastrointestinal bleeding in patients receiving long-term anticoagulant therapy Am J Med 84 1988 683 690
23. T.A. Rubin, M. Murdoch, and D.B. Nelson Acute GI bleeding in the setting of supratherapeutic international normalized ratio in patients taking warfarin: endoscopic diagnosis, clinical management, and outcomes Gastrointest Endosc 58 2003 369 373
24. J.G. Hashash, W. Shamseddeen, and A. Skoury Gross lower gastrointestinal bleeding in patients on anticoagulant and/or antiplatelet therapy: endoscopic findings, management, and clinical outcomes Journal of clinical gastroenterology 43 2009 36 42
25. FDA Advisory Committee Briefing Document. Boehringer Ingelheim. Dabigatran etexilate. 2010;1-168.
26. M. Patel, K. Mahaffey, and J. Garg Rivaroxaban versus Warfarin in nonvavular atrial fibrillation New Engl J Med 365 2011 883 891
27. C. Nessel, K. Mahaffey, and J. Piccini Incidence and outcomes of gastrointestinal hemorrhage in patients with atrial fibrillation treated with rivaroxaban or warfarin: results from the ROCKET AF trial Chest J [Internet] 2012 Accessed Dec 4, 2012;142(4-MeetingAbstracts):84A
28. G.C. Flaker, J.W. Eikelboom, and O. Shestakovska Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K Stroke 43 2012 3291 3297
29. Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. New Engl J Med. Epub 2013 March 13.
30. European Medicines Agency - Human medicines - European Medicines Agency updates patient and prescriber information for Pradaxa [Internet]. Accessed March 16, 2013. Available from: http://www.ema.europa.eu/ema/index.jsp?curl= pages/medicines/human/public-health-alerts/2012/05/human-pha-detail-000061. jsp&mid=WC0b01ac058001d126.
31. Drug Safety and Availability - FDA Drug Safety Communication: Update on the risk for serious bleeding events with the anticoagulant Pradaxa (dabigatran) [Internet]. Accessed March 16, 2013. Center for Drug Evaluation and Research; Available from: http://www.fda.gov/Drugs/DrugSafety/ucm326580.htm.
32. L. Kernan, S. Ito, and F. Shirazi Fatal gastrointestinal hemorrhage after a single dose of dabigatran Clin Tox 50 2012 571 573
33. S.E. Fellows, J.M. Rosini, and J.A. Curtis Hemorrhagic gastritis with dabigatran in a patient with renal insufficiency J Em Med 44 2012 e221 e225
34. M.K. Wychowski, and P.A. Kouides Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment Ann Pharmacother 46 2012 e10
35. B. Cryer, and M. Feldman Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans Gastroenterology 117 1999 17 25
36. R. Pisters, D.A. Lane, and R. Nieuwlaat A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey Chest 138 2010 1093 1100
37. J. Ansell, J. Hirsh, and E. Hylek Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 supp l6 2008 160S 198S
38. M.A. Anderson, T. Ben-Menachem, and S.I. Gan Management of antithrombotic agents for endoscopic procedures Gastrointest Endosc 70 2009 1060 1070
39. D. Garcia, Y.C. Barrett, and E. Ramacciotti Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants J Thromb Haemost 11 2013 245 252
40. Product information for Pradaxa. Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT 06877. December 2012.
41. Product information for Xarelto. Janssen Pharmaceuticals, Inc. Titusville, NJ 08560. November 2012.
42. Prescribing information for Eliquis. Pfizer, Inc. New York, NY 10017. December 2012.
43. M.A. Miyares, and K. Davis Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient AJHP 69 2012 1473 1484
44. J. Hirsh, G. Guyatt, and G.W. Albers Executive summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 Suppl6 2008 71S 109S
45. V. Fuster, L.E. Rydén, and D.S. Cannom ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences Europace 8 2006 651 745
46. D.A. Garcia, and C.B. Granger Anticoagulation, novel agents, and procedures: Can we pardon the interruption? Circulation 126 2012 255 257
47. J. Van Ryn, J. Stangier, and S. Haertter Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity Thromb Haemostasis 103 2010 1116 1127
48. E.S. Eerenberg, P.W. Kamphuisen, and M.K. Sijpkens Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects Circulation 124 2011 1573 1579
49. L.E. Dumkow, J.R. Voss, and M. Peters Reversal of dabigatran-induced bleeding with a prothrombin complex concentrate and fresh frozen plasma Am J Health-system Pharm 69 2012 1646 1650
50. I. Pragst, S.H. Zeitler, and B. Doerr Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model J Thrombosis Haemostasis 10 2012 1841 1848
51. J. Van Ryn, T. Litzenburger, and J. Schurer Reversal of anticoagulant activity of dabigatran and dabigatran-induced bleeding in rats by a specific antidote (antibody fragment) Circulation [Internet] 2012 Accessed Jan 2, 2013. Available from: http://circ.ahajournals.org/cgi/content/meeting
52. G. Lu, F.R. Deguzman, and S.J. Hollenbach A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa Nature Med [Internet] Mar 3, 2013 Accessed Mar 11, 2013; Available from: http://www.ncbi.nlm.nih.gov/pubmed/23455714
53. J. Stangier, K. Rathgen, and H. Stähle Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study Clinical Pharmacokinetics 49 2010 259 268
54. T.E. Warkentin, P. Margetts, and S.J. Connolly Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding Blood 119 2012 2172 2174
55. A.T. Wolf, S.K. Wasan, and J.R. Saltzman Impact of anticoagulation on rebleeding following endoscopic therapy for nonvariceal upper gastrointestinal hemorrhage Am J Gastroenterol 102 2007 290 296
56. J.H. Hwang, D.A. Fisher, and T. Ben-Menachem The role of endoscopy in the management of acute non-variceal upper GI bleeding Gastrointest Endosc 75 2012 1132 1138
57. S. Connolly, M. Ezekowitz, and Y. Salim Dabigatran versus warfarin in patients with atrial fibrillation New Engl J Med 361 2009 1139 1151
58. J.D. Douketis, A.C. Spyropoulos, and F.A. Spencer Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 suppl 2 2012 e326S e350S
59. Product monograph for Pradaxa. Boehringer Inhelheim Canada Ltd. Burlington, ON L7L 5H4. December 2012.
60. Product monograph for Xarelto. Bayer, Inc. Toronto, ON M9W 1G6. July 2012.
61. Product monograph for Eliquis. Pfizer Canada, Inc. Kirkland, QC H9J 2M5. November 2012.
62. J.I. Weitz, D.J. Quinlan, and J.W. Eikelboom Periprocedural management and approach to bleeding in patients taking dabigatran Circulation 126 2012 2428 2432
63. Advisory Committee Briefing Document. Dabigatran. B. Ingelheim. 2010.
64. J.S. Healey, J. Eikelboom, and J. Douketis Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the randomized evaluation of long-term anticoagulation therapy (RE-LY) randomized trial Circulation 126 2012 343 348
65. A. Komocsi, A. Vorobcsuk, and D. Kehl Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome Arch Int Med 172 2013 1537 1545
66. F. Andreotti, L. Testa, and G.G.L. Biondi-Zoccai Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients Eur Heart J 27 2006 519 526
67. L. Wallentin, R.G. Wilcox, and W.D. Weaver Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial Lancet 362 2003 789 797
68. J. Oldgren, A. Budaj, and C.B. Granger Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial Eur Heart J 32 2011 2781 2789
69. P.G. Steg, S.R. Mehta, and J.W. Jukema RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome Eur Heart J 32 2011 2541 2554
70. J.H. Alexander, R.D. Lopes, and S. James Apixaban with antiplatelet therapy after acute coronary syndrome New Eng J Med 365 2011 699 708
71. J.L. Mega, E. Braunwald, and S. Mohanavelu Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial Lancet 374 2009 29 38
72. J.L. Mega, E. Braunwald, and S. Wiviott Rivaroxaban in patients with a recent acute coronary syndrome New Eng J Med 366 2012 9 19
73. J.H. Alexander, R.C. Becker, and D.L. Bhatt Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the apixaban for prevention of acute ischemic and safety events (APPRAISE) trial Circulation 119 2009 2877 2885
74. N. Abraham Novel oral anticoagulants and gastrointestinal bleeding: a case for cardiogastroenterology Clin Gastroenterol Hepatol 11 2013 324 328 Epub 2013 Jan 21
75. P. Bytzer, S.J. Connolly, and S. Yang Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial Clin Gastroenterol Hepatol 11 2013 246 252
76. A. Hoffman, and P.R. Galle Gastrointestinal disorders and dabigatran Scand J Gastroenterol 48 2012 9 16
77. G.Y.H. Lip, F. Andreotti, and L. Fauchier Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis Europace 13 2011 723 746